
OxThera
Founded Year
2005Stage
Unattributed VC - III | AliveTotal Raised
$53.66MLast Raised
$34.05M | 7 yrs agoAbout OxThera
OxThera is a biopharmaceutical company with products in late stage clinical development focusing on Primary and Secondary Hyperoxaluria. OxThera's intellectual property includes worldwide patents for compositions and treatment of hyperoxaluria with bacteria, and enzymes. Oxabact holds Orphan Drug designations in Europe and in the US for the treatment of primary hyperoxaluria.
Loading...
Loading...
OxThera Patents
OxThera has filed 16 patents.
The 3 most popular patent topics include:
- oxalates
- gastrointestinal tract disorders
- kidney diseases

Application Date | Grant Date | Title | Related Topics | Status |
---|---|---|---|---|
9/27/2018 | 4/27/2021 | Ion channels, Kidney diseases, Rare diseases, Gastrointestinal tract disorders, Autosomal recessive disorders | Grant |
Application Date | 9/27/2018 |
---|---|
Grant Date | 4/27/2021 |
Title | |
Related Topics | Ion channels, Kidney diseases, Rare diseases, Gastrointestinal tract disorders, Autosomal recessive disorders |
Status | Grant |
Latest OxThera News
Sep 7, 2023
Companies Covered Takeda Pharmaceutical Company Limited, Merck KGaA, Zealand Pharma A/S, OxThera, VectivBio AG, 9 Meters Biopharma, Inc., Nutrinia Ltd., Hanmi Pharm.Co., Ltd., Pharmascience, Inc. Key Findings of the Market Report In 2021, a sizable portion of the distribution channel segment's revenue is anticipated to come from online and retail pharmacies. The dominance is attributable to the rise in retail and online pharmacies in nations like the United States, the United Kingdom, India, and others. A large variety of GLP-2-based pipeline items for short bowel syndrome is the primary reason for the GLP-2 segment's dominance. Hospital pharmacies are anticipated to occupy a sizable portion of the market due to the industry's growing need for cutting-edge medications to treat ailments like Crohn's disease, one of the leading causes of short bowel syndrome. Market Trends for Short Bowel Syndrome Over the past several years, small bowel syndrome has become more common everywhere. The rise in patients receiving whole parenteral nourishment can be blamed for this. Short bowel syndrome is predicted to have a prevalence of four cases per million and an incidence of three cases per million. The precise incidence of the illness is unknown, and it is assumed based on the number of persons receiving parenteral feeding. The rise in frequency and incidence of uncommon diseases is probably what will drive the global market's expansion. There are now many additional treatments being tested in clinical trials for the management of short bowel syndrome, and there are no approved medications for the illness worldwide. The market's best insights begin with a simple request – get your sample now: https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=13346 Short Bowel Syndrome Market Regional Outlook Various reasons are propelling the growth of the short bowel syndrome market in different regions. These are: The expansion of the short bowel syndrome market in North America is being driven by the presence of a sizable patient pool embracing cutting-edge medications and needing new treatment alternatives. It is projected that the availability of a broad variety of pipeline items as well as the extended usage of authorized pharmaceuticals to treat adults as well as kids would support market growth in this area over the course of the projection period. Asia Pacific is predicted to have the most rapid CAGR throughout the projection period. The market expansion in this area is fueled by the direct participation of large companies, substantial investments in research and development for the creation of novel pharmaceuticals, and a growing emphasis on GLP-2-based medication clinical trials. Global Short Bowel Syndrome Market: Key Players Market players for short bowel syndrome are involved in regulatory approvals, the creation of new services, acquisitions, and joint ventures with other businesses. The short bowel syndrome market will probably grow internationally as a result of these tactics over the coming years. The following companies are well-known participants in the global short bowel syndrome market: Takeda Pharmaceutical Company Limited 2021 The FDA designated Apraglutide, a long-acting GLP-2 analog of the next generation being researched for uncommon gastrointestinal (GI) illnesses, as an orphan drug for the treatment of acute graft-versus-host disease (aGVHD). Receiving an allogeneic hematopoietic stem cell transplant can cause GVHD, a severe, uncommon illness in which the patient's healthy cells are attacked by the donor's immune cells. In the first quarter of 2022, VectivBio AG intends to start a phase 2 study testing Apraglutide for the treatment of aGVHD. Hanmi Pharm. Co. Ltd. 2021 Hanmi Pharm Co. Ltd. disclosed that the United States Food and Drug Administration has given LAPS GLP-2 Analog (HM15912), a treatment for short bowel syndrome, fast-track designation. With the use of the company's platform technology, called Labscovery, a novel biopharmaceutical called LAPS GLP-2 Analog is being created for short-bowel syndrome. The condition has a survival rate of under 50% and impairs children and teenagers' growth adversely. It affects around 24.5 out of every 100,000 infants. For Customization or Any Other Queries, Get in Touch with Our Industry Experts at - https://www.transparencymarketresearch.com/sample/sample.php?flag=CR&rep_id=13346 Global Short Bowel Syndrome Market Segmentation Product About Transparency Market Research Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. The firm scrutinizes factors shaping the dynamics of demand in various markets. The insights and perspectives on the markets evaluate opportunities in various segments. The opportunities in the segments based on source, application, demographics, sales channel, and end-use are analysed, which will determine growth in the markets over the next decade. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision-makers, made possible by experienced teams of Analysts, Researchers, and Consultants. The proprietary data sources and various tools & techniques we use always reflect the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in all of its business reports. Contact:
OxThera Frequently Asked Questions (FAQ)
When was OxThera founded?
OxThera was founded in 2005.
Where is OxThera's headquarters?
OxThera's headquarters is located at Regeringsgatan 111, Stockholm.
What is OxThera's latest funding round?
OxThera's latest funding round is Unattributed VC - III.
How much did OxThera raise?
OxThera raised a total of $53.66M.
Who are the investors of OxThera?
Investors of OxThera include Kurma Partners, IDInvest Partners, Industrifonden, Flerie Invest, Sunstone Capital and 10 more.
Who are OxThera's competitors?
Competitors of OxThera include Cerecin, MaxCyte, NGM Biopharmaceuticals, Pique Therapeutics, BIND Therapeutics and 7 more.
Loading...
Compare OxThera to Competitors
EnzymeRx is a private, clinical stage biotechnology company developing uricase-PEG 20 for the treatment of resistant and refractory gout and related indications in which hyperuricemia plays a causative role.
Arcion Therapeutics applies breakthroughs in neuroscience to advance the treatment of chronic pain. The company focuses on topical treatments to provide pain relief with convenient application and reduced systemic side effects. Arcion's core technology is based on research which showed that in many neuropathic pain conditions, the signal that triggers pain actually arises at the level of the skin. This finding provides a strong biological rationale for developing topically delivered drugs to target the pain at the source - the pain receptors in the skin. Arcion's product pipeline comprises multiple candidates to treat neuropathic pain. ARC-4558 is a topical 0.1% clonidine gel being developed for the treatment of painful diabetic neuropathy (PDN). It is a clear, water-based, fast-drying gel that provides pain relief that rivals approved oral drugs. ARC-4558 has a minimal side-effect profile with low/undetectable systemic levels of clonidine with over 600 patients treated in clinical trials to date.
AngioChem is a clinical-stage biotechnology discovering and developing drugs that are capable of crossing the blood-brain barrier to treat brain diseases. The company's EPiC platform aims to solve the key problem for crossing the blood-brain barrier by developing drugs that use a receptor-based approach.
Scientists at Epeius Biotechnologies have developed a targeted delivery system (TDS) that can transport genes or other therapeutic agents directly to diseased areas in the body. This pathotropic, or disease-seeking, technology has enabled the company to develop Rexin-G, a tumor-targeted, injectable gene delivery system that has demonstrated remarkable safety and single-agent efficacy in clinical trials internationally. Rexin-G is currently in clinical trials for pancreatic cancer in the U.S. ƒƒ‚ƒš‚" where it has achieved FDA orphan drug status ƒƒ‚ƒš‚" and has accelerated approval in the Philippines for the treatment of all solid tumors that are resistant to standard chemotherapy. The company's international clinical outreach with Rexin-G has enabled us to expedite further demonstrations that Rexin-G is highly active in a broad spectrum of chemo-resistant tumor types with efficacy and excellent safety profiles. The company are a biopharmaceutical company focused on expanding the therapeutic utility and commercialization of the company's pathotropic approach to disease treatment through internal development and commercialization of the company's oncology products and cancer vaccines, and through strategic partnerships in additional areas of oncology, immunology, cardiovascular, ocular, and wound healing applications, precision targeted diagnostics, and stem cell technologies.

Cerecin is a healthcare company that focuses on brain health. The company develops a range of products including pharmaceuticals, medical foods, diagnostics, medical devices, and e-health products, all aimed at addressing conditions ranging from memory impairment to severe neurological diseases. Cerecin was formerly known as Accera. It was founded in 2001 and is based in Singapore, Singapore.
GlycoMar Limited is the European centre for marine biotechnology and glycobiology. GlycoMar is an Research & Development and development company pursuing untapped biological and chemical diversity to identify drug candidates from marine organisms.
Loading...